Sanofi reported net cash proceeds of about 10 billion ($10.7 billion) from the deal, which it had outlined earlier in 2024.

Six months after entering talks with U.S. private equity firm Clayton, Dubilier & Rice (CD&R), Sanofi has closed a deal to ...

Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of ...

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal ...

Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in ...

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in French pharma major Sanofi's strategy. Sanofi announced today the closing of the sale to US private ...

The closing of the sale of a controlling stake in Opella to CD&R is anticipated in Q2Stay Ahead of the Market: Discover outperforming ...

In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER 5. Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit ...

In October 2023, Sanofi announced its intention to separate its Consumer Healthcare (CHC) unit through the creation of a publicly listed entity headquartered in Paris to be called Opella.

The brand tries to answer a question: can we follow the 5-second rule to eat food after it falls on the floor? SÃO PAULO, ...

Business EPS was EUR 1.79, up 15.7% at CER and up 17.0% reported. Reports Q1 IRFS net sales EUR 9.9B, up 10.8% reported and up 9.7% at CER.

Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling ...